Unngå å anbefale, skrive ut eller bruke hostedempende eller slimløsende medisiner til barn.
Unngå rutinemessig bruk av steroider og bronkodilatorer hos spedbarn med bronkiolitt.
Unngå å rutinemessig forlenge intravenøs antibiotika for behandling av alvorlige infeksjoner, men vurder å bytte til peroral behandling så snart den kliniske tilstanden har bedret seg.
Unngå rutinemessig bruk av antibiotika hos barn med akutt mellomørebetennelse når spontan tilbakegang forventes.
Unngå å forskrive antibiotika til nyfødte uten kliniske tegn på sepsis.
Unngå rutinemessig forlenget innleggelse av febrile spedbarn som framstår som friske, når blodkulturer har vært negative i 24 til 36 timer, dersom tilstrekkelig poliklinisk oppfølging kan sikres.
Unngå å fortsette
antibiotikabehandling for mistenkt nyfødtsepsis i mer enn 36-48 timer uten
klar mistanke om bakteriell infeksjon.
Unngå å ta screeningpaneler (IgE-tester) for matallergier uten en grundig sykehistorie som gir mistanke om matallergi.
Unngå å rekvirere urindyrkning hos febrile barn over 2 måneder med luftveisinfeksjon.
Unngå rutinemessig forskrivning av syrehemmere og motilitetsmidler til spedbarn med gastroøsofageal refluks.
New ways to test high-risk medical devices.
Manufacturers of medical devices need to test their products before being allowed to market them. Specifically, they require clinical data showing their medical device is safe and efficient. In this context, the EU-funded CORE-MD project will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators. The project will propose how new trial designs can contribute and suggest ways to aggregate real-world data from medical device registries.
It will also conduct multidisciplinary workshops to propose a hierarchy of levels of evidence from clinical investigations, as well as educational and training objectives for all stakeholders, to build expertise in regulatory science in Europe. CORE–MD will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators, to achieve an appropriate balance between innovation, safety, and effectiveness. A unique collaboration between medical associations, regulatory agencies, notified bodies, academic institutions, patients’ groups, and health technology assessment agencies, will systematically review methodologies for the clinical investigation of high-risk medical devices, recommend how new trial designs can contribute, and advise on methods for aggregating real-world data from medical device registries with experience from clinical practice The consortium is led by the European Society of Cardiology and the European Federation of National Associations of Orthopaedics and Traumatology, and involves all 33 specialist medical associations that are members of the Biomedical Alliance in Europe.
